(Q39867512)

15 September 2017

title

3D QSAR models built on structure-based alignments of Abl tyrosine kinase inhibitors (English)

1 reference

15 September 2017

2

1 reference

15 September 2017

0 references

Giovanni Maga

5

1 reference

ORCID Public Data File 2021

Maurizio Botta

10

object named as

Maurizio Botta

1 reference

15 September 2017

Federico Falchi

1

1 reference

15 September 2017

Fabio Carraro

3

1 reference

15 September 2017

Antonella Naldini

4

1 reference

15 September 2017

Emmanuele Crespan

6

1 reference

15 September 2017

Silvia Schenone

7

1 reference

15 September 2017

Olga Bruno

8

1 reference

15 September 2017

Chiara Brullo

9

1 reference

15 September 2017

publication date

1 June 2009

1 reference

15 September 2017

1 reference

15 September 2017

volume

4

1 reference

15 September 2017

issue

6

1 reference

15 September 2017

page(s)

976-987

1 reference

Combinatorial library design using a multiobjective genetic algorithm

15 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800441

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800441

7 January 2021

Chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800441

7 January 2021

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800441

7 January 2021

A Src-like inactive conformation in the abl tyrosine kinase domain

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800441

7 January 2021

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800441

7 January 2021

Imatinib: a review of its use in chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800441

7 January 2021

Current status of therapy for chronic myeloid leukemia: a review of drug development

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800441

7 January 2021

Inhibitors of ABL and the ABL-T315I mutation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800441

7 January 2021

Last findings on dual inhibitors of abl and SRC tyrosine-kinases.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800441

7 January 2021

Inhibition of Bcr-Abl phosphorylation and induction of apoptosis by pyrazolo[3,4-d]pyrimidines in human leukemia cells

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800441

7 January 2021

Structure-based optimization of pyrazolo[3,4-d]pyrimidines as Abl inhibitors and antiproliferative agents toward human leukemia cell lines.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800441

7 January 2021

Synthesis, biological evaluation and docking studies of 4-amino substituted 1H-pyrazolo[3,4-d]pyrimidines

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800441

7 January 2021

The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800441

7 January 2021

Docking, 3D-QSAR studies and in silico ADME prediction on c-Src tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800441

7 January 2021

Identification of a novel pyrazolo[3,4-d]pyrimidine able to inhibit cell proliferation of a human osteogenic sarcoma in vitro and in a xenograft model in mice

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800441

7 January 2021

Synthesis and Biological Evaluation ofN-Pyrazolyl-N‘-alkyl/benzyl/phenylureas: a New Class of Potent Inhibitors of Interleukin 8-Induced Neutrophil Chemotaxis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800441

7 January 2021

Substituted pyrazolo[3,4-b]pyridines as potent A1 adenosine antagonists: synthesis, biological evaluation, and development of an A1 bovine receptor model

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800441

7 January 2021

Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800441

7 January 2021

Efficient docking of peptides to proteins without prior knowledge of the binding site

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800441

7 January 2021

Identifiers

DOI

10.1002/CMDC.200800441

1 reference

15 September 2017

1 reference